BioMarin Pharmaceutical Statistics
Want to see BMRN full AI Analyst Report?
BioMarin Pharmaceutical (BMRN) Stock Statistics & Valuation Metrics
Total Valuation
BioMarin Pharmaceutical has a market cap or net worth of $11.07B. The enterprise value is $15.09B.
- Market Cap
- $11.07B
- Enterprise Value
- $15.09B
Share Statistics
BioMarin Pharmaceutical has 193,694,730 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 193,694,730
- Owned by Insiders
- 0.45%
- Owned by Institutions
- 61.89%
Financial Efficiency
BioMarin Pharmaceutical’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.64%.
- Return on Equity (ROE)
- 0.06
- Return on Assets (ROA)
- 0.05
- Return on Invested Capital (ROIC)
- 5.64%
- Return on Capital Employed (ROCE)
- 0.08
- Revenue Per Employee
- 1.00M
- Profits Per Employee
- 108.32K
- Employee Count
- 3,221
- Asset Turnover
- 0.42
- Inventory Turnover
- 0.57
Valuation Ratios
The current PE Ratio of BioMarin Pharmaceutical is -648.11. BioMarin Pharmaceutical’s PEG ratio is 6.27.
- PE Ratio
- -648.11
- PS Ratio
- 3.09
- PB Ratio
- 1.80
- Price to FCF
- 20.25
- Price to Operating Cash Flow
- 16.69
- PEG Ratio
- 6.27
Income Statement
In the last 12 months, BioMarin Pharmaceutical had revenue of 3.22B and earned 348.90M in profits. Earnings per share was 1.82.
- Revenue
- 3.22B
- Gross Profit
- 2.48B
- Operating Income
- 533.48M
- Pretax Income
- 482.48M
- Net Income
- 348.90M
- EBITDA
- 572.94M
- Earnings Per Share (EPS)
- 1.82
Cash Flow
In the last 12 months, operating cash flow was 676.62M and capital expenditures -118.75M, giving a free cash flow of 557.86M billion.
- Operating Cash Flow
- 676.62M
- Free Cash Flow
- 557.86M
- Free Cash Flow per Share
- 2.88
Dividends & Yields
BioMarin Pharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 4.95%
- Earnings Yield
- -0.17%
Stock Price Statistics
- Beta
- 0.51
- 52-Week Price Change
- 6.19%
- 50-Day Moving Average
- 59.72
- 200-Day Moving Average
- 58.52
- Relative Strength Index (RSI)
- 54.64
- Average Volume (3m)
- 2.20M
Important Dates
BioMarin Pharmaceutical upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 02, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- ―
Financial Position
BioMarin Pharmaceutical as a current ratio of 5.21, with Debt / Equity ratio of 10.56%
- Current Ratio
- 5.21
- Quick Ratio
- 3.50
- Debt to Market Cap
- 0.05
- Net Debt to EBITDA
- -1.17
- Interest Coverage Ratio
- 48.95
Taxes
In the past 12 months, BioMarin Pharmaceutical has paid 133.58M in taxes.
- Income Tax
- 133.58M
- Effective Tax Rate
- 0.28
Enterprise Valuation
BioMarin Pharmaceutical EV to EBITDA ratio is 33.05, with an EV/FCF ratio of 26.38.
- EV to Sales
- 4.03
- EV to EBITDA
- 33.05
- EV to Free Cash Flow
- 26.38
- EV to Operating Cash Flow
- 21.75
Balance Sheet
BioMarin Pharmaceutical has $736.01M in cash and marketable securities with $4.19B in debt, giving a net cash position of -$3.45B billion.
- Cash & Marketable Securities
- $736.01M
- Total Debt
- $4.19B
- Net Cash
- -$3.45B
- Net Cash Per Share
- -$17.83
- Tangible Book Value Per Share
- $4.20
Margins
Gross margin is 75.42%, with operating margin of 6.51%, and net profit margin of -0.52%.
- Gross Margin
- 75.42%
- Operating Margin
- 6.51%
- Pretax Margin
- 1.19%
- Net Profit Margin
- -0.52%
- EBITDA Margin
- 12.18%
- EBIT Margin
- 4.93%
Analyst Forecast
The average price target for BioMarin Pharmaceutical is $88.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $88.00
- Price Target Upside
- 50.87% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 22
- Revenue Growth Forecast
- 19.76%
- EPS Growth Forecast
- -103.57%
Scores
- Smart Score
- 7
- AI Score
- 59
